Drug intelligence / Profile preview

ZN002

Development stage: Discontinued
Lead developer: Zerion Pharma
Modality: Small Molecules
Administration: Oral

Overview

**ZN002** is a small molecule reformulation of a marketed cancer drug developed by Zerion Pharma using its proprietary Dispersome® technology to enhance bioavailability. In preclinical dog studies, ZN002 achieved bioequivalence to the originator with only 25% of the active drug amount, increasing bioavailability 4-fold and potentially reducing tablet burden for cancer patients.[3][7] The program targets neoplasms and was discontinued at the preclinical stage.[5]

Beyond the preview

Go deeper on ZN002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZN002.

Explore the full profile